RHBC
IDIX

R.H. Bluestein & Co’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

R.H. Bluestein & Co’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,500
Closed -$69K – 402
2013
Q4 		$69K Sell
11,500
-22,000
-66% -$102K ﹤0.01% 355
2013
Q3 		$174K Buy
+33,500
New +$147K 0.01% 328

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

R.H. Bluestein & Co's IDIX Position: Q1 2014 in Review

R.H. Bluestein & Co sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q1 2014, closing a stake of 11,500 shares — an estimated $69K sold.

R.H. Bluestein & Co first reported a position in IDIX in Q3 2013 and held it in 2 quarters. The position peaked at $174K in Q3 2013. 96 funds tracked by Wall St. Rank hold IDIX as of Q1 2014.

  • R.H. Bluestein & Co reported no remaining IDENIX PHARMACEUTICALS INC position as of Q1 2014 after selling out during the quarter.
  • R.H. Bluestein & Co sold 11,500 IDENIX PHARMACEUTICALS INC shares in Q1 2014, an estimated $69K.
  • R.H. Bluestein & Co first reported a position in IDENIX PHARMACEUTICALS INC in Q3 2013 and held it in 2 quarters.
  • R.H. Bluestein & Co's IDENIX PHARMACEUTICALS INC position peaked at $174K in Q3 2013.
  • 96 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q1 2014.

Based on R.H. Bluestein & Co's 13F filing for Q1 2014, filed 13 May 2014.